Literature DB >> 8097348

Ophthalmic manifestations of epidemic nephropathy.

O Pärssinen1, A Klemetti, E Rossi-Rautiainen, T Forslund.   

Abstract

An ophthalmic examination was performed on 29 epidemic nephropathy patients consequently treated in the Central Hospital of Central Finland during the acute phase of the disease. Twenty-six of those patients were reexamined after an interval of one month. In the acute phase of the disease pathological ophthalmic changes were found in 15 cases (52%). The symptoms observed were conjunctival injection, oedema, flare and cell reaction in anterior chamber, anisochoria, retinal oedema, acute glaucoma and myopic shift of refraction. The main effect of disease on intraocular pressure was pressure-lowering. The myopic shifts were not dependent on initial refraction. In one case of acute glaucoma this shift could be explained by swelling and forward movement of the lens.

Entities:  

Mesh:

Year:  1993        PMID: 8097348     DOI: 10.1111/j.1755-3768.1993.tb04972.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  4 in total

1.  [Bilateral acute angle-closure glaucoma due to an infection with Hantavirus].

Authors:  A Zimmermann; B Lorenz; W Schmidt
Journal:  Ophthalmologe       Date:  2011-08       Impact factor: 1.059

2.  Myopic shift and its mechanism in nephropathia epidemica or Puumala virus infection.

Authors:  M Kontkanen; T Puustjärvi; J Lähdevirta
Journal:  Br J Ophthalmol       Date:  1994-12       Impact factor: 4.638

3.  Changes in the Ocular Parameters of Patients with Graves' Disease after Antithyroid Drug Treatment.

Authors:  Je-Sang Lee; Dong-Ju Yeom; Seung-Kwan Nah; Bo-Yeon Kim; Sun-Young Jang
Journal:  Medicina (Kaunas)       Date:  2021-04-25       Impact factor: 2.430

Review 4.  Central Nervous System and Ocular Manifestations in Puumala Hantavirus Infection.

Authors:  Nina Hautala; Terhi Partanen; Anna-Maria Kubin; Heikki Kauma; Timo Hautala
Journal:  Viruses       Date:  2021-05-31       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.